NMR screening and hit validation in fragment based drug discovery

Current Topics in Medicinal Chemistry

Volumn 11, Issue 1, 2011, Pages 43-67

  Campos Olivas, Ramón ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

Drug discovery; Fragment screening; Fragment based; Hit; Library screening; NMR; Protein ligand interaction; Review

Indexed keywords

ADENOSINE TRIPHOSPHATE; BACCATIN III; CARBOXYLTRANSFERASE; DOCKING PROTEIN; EPOTHILONE A; FATTY ACID BINDING PROTEIN; HEAT SHOCK PROTEIN 90 INHIBITOR; LIGAND; NITROGEN 15; PEPTIDE FRAGMENT; PEPTIDE LIBRARY; RECEPTOR;

ARTICLE; BINDING AFFINITY; BINDING SITE; DIFFUSION; DRUG RECEPTOR BINDING; HUMAN; ISOTOPE LABELING; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR OVERHAUSER EFFECT; PHYSICAL CHEMISTRY; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTON NUCLEAR MAGNETIC RESONANCE; SCREENING; SPIN LABELING; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY;

DRUG DISCOVERY; HUMANS; LIGANDS; MACROMOLECULAR SUBSTANCES; MAGNETIC RESONANCE SPECTROSCOPY; SMALL MOLECULE LIBRARIES;

EID: 78649931541     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802611793611887     Document Type: Article

References (235)

1. Wüthrich, K. NMR of Proteins and Nucleic Acids; Wiley: New York, 1986.
2. Cavanagh, J.; Fairbrother, W.; Palmer, A. G., 3rd; Rance, M.; Skelton, N. J. Protein NMR Spectroscopy, Principles and Practice; Elsevier Academic Press, USA, 2007.
3. Jahnke, W. Perspectives of biomolecular NMR in drug discovery: the blessing and curse of versatility. J. Biomol., NMR 2007, 39, 87-90.
4. Jhoti, H.; Leach, A. R. Eds. Structure-based Drug Discovery; Springer: USA, 2007.
5. Jahnke, W.; Erlanson, D. A. Fragment-based approaches in drug discovery; Wiley-VCH: Weinheim, Germany, 2006.
6. Zartler, E. R.; Shapiro, M. J. Eds. Fragment-Based Drug Discovery: A Practical Approach; Wiley Interscience. USA, 2008.
7. Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragmentbased lead discovery. Nat. Rev. Drug Discov., 2004, 3, 660-672.
8. Erlanson, D. A.; Hansen, S. K. Making drugs on proteins: sitedirected ligand discovery for fragment-based lead assembly. Curr. Opin. Chem. Biol., 2004, 8, 399-406.
9. Carr, R. A.; Congreve, M.; Murray, C. W.; Rees, D. C. Fragmentbased lead discovery: leads by design. Drug Discov. Today, 2005, 10, 987-992.
10. Leach, A. R.; Hann, M. M.; Burrows, J. N.; Griffen, E. J. Fragment screening: an introduction. Mol. Biosyst., 2006, 2, 430-446.
11. Hajduk, P. J. Fragment-based drug design: how big is too big? J. Med. Chem., 2006, 49, 6972-6976.
12. Klages, J.; Coles, M.; Kessler, H. NMR-based screening: a powerful tool in fragment-based drug discovery. Analyst, 2007, 132, 693-705.
13. Fattori, D.; Squarcia, A.; Bartoli, S. Fragment-based approach to drug lead discovery: overview and advances in various techniques. Drugs R. D., 2008, 9, 217-227.
14. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR. Science, 1996, 274, 1531-1534.
15. Hajduk, P. J.; Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov., 2007, 6, 211-219.
16. Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands. Proc. Natl. Acad. Sci., USA, 1999, 96, 9997-10002.
17. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today, 2004, 9, 430-431.
18. Abad-Zapatero, C.; Metz, J. T. Ligand efficiency indices as guideposts for drug discovery. Drug Discov. Today, 2005, 10, 464-469.
19. Erlanson, D. A. Fragment-based lead discovery: a chemical update. Curr. Opin. Biotechnol., 2006, 17, 643-652.
20. Alex, A. A.; Flocco, M. M. Fragment-based drug discovery: what has it achieved so far? Curr. Top. Med. Chem., 2007, 7, 1544-1567.
21. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. Recent developments in fragment-based drug discovery. J. Med. Chem., 2008, 51, 3661-3680.
22. de Kloe, G. E.; Bailey, D.; Leurs, R.; de Esch, I. J. Transforming fragments into candidates: small becomes big in medicinal chemistry. Drug Discov. Today, 2009, 14, 630-646.
23. Chessari, G.; Woodhead, A. J. From fragment to clinical candidate- -a historical perspective. Drug Discov. Today, 2009, 14, 668-675.
24. Hartshorn, M. J.; Murray, C. W.; Cleasby, A.; Frederickson, M.; Tickle, I. J.; Jhoti, H. Fragment-based lead discovery using X-ray crystallography. J. Med. Chem., 2005, 48, 403-413.
25. Jhoti, H.; Cleasby, A.; Verdonk, M.; Williams, G. Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr. Opin. Chem. Biol., 2007, 11, 485-493.
26. Neumann, T.; Junker, H. D.; Schmidt, K.; Sekul, R. SPR-based fragment screening: advantages and applications. Curr. Top. Med. Chem., 2007, 7, 1630-1642.
27. Proll, F.; Fechner, P.; Proll, G. Direct optical detection in fragmentbased screening. Anal. Bioanal. Chem., 2009, 393, 1557-1562.
28. Hofstadler, S. A.; Griffey, R. H. Analysis of noncovalent complexes of DNA and RNA by mass spectrometry. Chem. Rev., 2001, 101, 377-390.
29. Erlanson, D. A.; Wells, J. A.; Braisted, A. C. Tethering: fragmentbased drug discovery. Annu. Rev. Biophys. Biomol. Struct., 2004, 33, 199-223.
30. Hesterkamp, T.; Barker, J.; Davenport, A.; Whittaker, M. Fragment based drug discovery using fluorescence correlation: spectroscopy techniques: challenges and solutions. Curr. Top. Med. Chem., 2007, 7, 1582-1591.
31. Ericsson, U. B.; Hallberg, B. M.; Detitta, G. T.; Dekker, N.; Nordlund, P. Thermofluor-based high-throughput stability optimization of proteins for structural studies. Anal. Biochem., 2006, 357, 289-298.
32. Diercks, T.; Coles, M.; Kessler, H. Applications of NMR in drug discovery. Curr. Opin. Chem. Biol., 2001, 5, 285-291.
33. Pellecchia, M.; Sem, D. S.; Wuthrich, K. NMR in drug discovery. Nat. Rev. Drug Discov., 2002, 1, 211-219.
34. Stockman, B. J.; Dalvit, C. NMR screening techniques in drug discovery and drug design. Prog. Nucl. Magn. Reson. Spectrosc., 2002, 41, 187-231.
35. Coles, M.; Heller, M.; Kessler, H. NMR-based screening technologies. Drug Discov. Today, 2003, 8, 803-810.
36. Meyer, B.; Peters, T. NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew Chem. Int. Ed. Engl., 2003, 42, 864-890.
37. Ross, A.; Senn, H. Automation of biomolecular NMR screening. Curr. Top. Med. Chem., 2003, 3, 55-67.
38. Zartler, E. R.; Yan, J.; Mo, H.; Kline, A. D.; Shapiro, M. J. 1D NMR Methods in ligand-receptor interactions. Curr. Top. Med. Chem., 2003, 3, 25-37.
39. Homans, S. W. NMR spectroscopy tools for structure-aided drug design. Angew Chem. Int. Ed. Engl., 2004, 43, 290-300.
40. Lepre, C. A.; Moore, J. M.; Peng, J. W. Theory and applications of NMR-based screening in pharmaceutical research. Chem. Rev., 2004, 104, 3641-3676.
41. Peng, J. W.; Moore, J.; Abdul-Manan, N. NMR experiments for lead generation in drug discovery. Prog. Nucl. Magn. Reson. Spectrosc., 2004, 44, 225-256.
42. Betz, M.; Saxena, K.; Schwalbe, H. Biomolecular NMR: a chaperone to drug discovery. Curr. Opin. Chem. Biol., 2006, 10, 219-225.
43. Hubbard, R. E.; Davis, B.; Chen, I.; Drysdale, M. J. The SeeDs approach: integrating fragments into drug discovery. Curr. Top. Med. Chem., 2007, 7, 1568-1581.
44. Zartler, E. R.; Mo, H. Practical aspects of NMR-based fragment discovery. Curr. Top. Med. Chem., 2007, 7, 1592-1599.
45. Skinner, A. L.; Laurence, J. S. High-field solution NMR spectroscopy as a tool for assessing protein interactions with small molecule ligands. J. Pharm. Sci., 2008, 97, 4670-4695.
46. Pellecchia, M.; Bertini, I.; Cowburn, D.; Dalvit, C.; Giralt, E.; Jahnke, W.; James, T. L.; Homans, S. W.; Kessler, H.; Luchinat, C.; Meyer, B.; Oschkinat, H.; Peng, J.; Schwalbe, H.; Siegal, G. Perspectives on NMR in drug discovery: a technique comes of age. Nat. Rev. Drug Discov., 2008, 7(9), 738-745.
47. Ludwig, C.; Guenther, U. L. Ligand based NMR methods for drug discovery. Front Biosci., 2009, 14, 4565-4574.
48. Dalvit, C. NMR methods in fragment screening: theory and a comparison with other biophysical techniques. Drug Discov. Today, 2009, 14, 1051-1057.
49. Albert, J. S.; Blomberg, N.; Breeze, A. L.; Brown, A. J.; Burrows, J. N.; Edwards, P. D.; Folmer, R. H.; Geschwindner, S.; Griffen, E. J.; Kenny, P. W.; Nowak, T.; Olsson, L. L.; Sanganee, H.; Shapiro, A. B. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. Curr. Top. Med. Chem., 2007, 7, 1600-1629.
50. Sanders, W. J.; Nienaber, V. L.; Lerner, C. G.; McCall, J. O.; Merrick, S. M.; Swanson, S. J.; Harlan, J. E.; Stoll, V. S.; Stamper, G. F.; Betz, S. F.; Condroski, K. R.; Meadows, R. P.; Severin, J. M.; Walter, K. A.; Magdalinos, P.; Jakob, C. G.; Wagner, R.; Beutel, B. A. Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization. J. Med. Chem., 2004, 47, 1709-1718.
51. Peterson, J. R.; Golemis, E. A. Autoinhibited proteins as promising drug targets. J. Cell. Biochem., 2004, 93, 68-73.
52. Spoerner, M.; Graf, T.; Konig, B.; Kalbitzer, H. R. A novel mechanism for the modulation of the Ras-effector interaction by small molecules. Biochem. Biophys. Res. Commun., 2005, 334, 709-713.
53. Chen, Y.; Shoichet, B. K. Molecular docking and ligand specificity in fragment-based inhibitor discovery. Nat. Chem. Biol., 2009, 5, 358-364.
54. Fielding, L. NMR methods for the determination of protein-ligand dissociation constants. Curr. Top. Med. Chem., 2003, 3, 39-53.
55. Fielding, L. NMR methods for the determination of protein-ligand dissociation constants. Prog. Nucl. Magn. Reson. Spectrosc., 2007, 51, 219-242.
56. Dalvit, C.; Flocco, M.; Knapp, S.; Mostardini, M.; Perego, R.; Stockman, B. J.; Veronesi, M.; Varasi, M. High-throughput NMRbased screening with competition binding experiments. J. Am. Chem. Soc., 2002, 124, 7702-7709.
57. Jahnke, W.; Floersheim, P.; Ostermeier, C.; Zhang, X.; Hemmig, R.; Hurth, K.; Uzunov, D. P. NMR reporter screening for the detection of high-affinity ligands. Angew Chem. Int. Ed. Engl., 2002, 41, 3420-3423.
58. Siriwardena, A. H.; Tian, F.; Noble, S.; Prestegard, J. H. A straightforward NMR-spectroscopy-based method for rapid library screening. Angew Chem. Int. Ed. Engl., 2002, 41, 3454-3457.
59. Dalvit, C. Theoretical analysis of the competition ligand-based NMR experiments and selected applications to fragment screening and binding constant measurements. Concepts Magn. Reson. Part A., 2008, 32A, 341-372.
60. Dalvit, C.; Fagerness, P. E.; Hadden, D. T.; Sarver, R. W.; Stockman, B. J. Fluorine-NMR experiments for high-throughput screening: theoretical aspects, practical considerations, and range of applicability. J. Am. Chem. Soc., 2003, 125, 7696-7703.
61. Manzenrieder, F.; Frank, A. O.; Kessler, H. Phosphorus NMR spectroscopy as a versatile tool for compound library screening. Angew. Chem. Int. Ed. Engl., 2008, 47, 2608-2611.
62. Feliz, M.; Garcia, J.; Aragon, E.; Pons, M. Fast 2D NMR ligand screening using Hadamard spectroscopy. J. Am. Chem. Soc., 2006, 128, 7146-7147.
63. Felli, I. C.; Brutscher, B. Recent advances in solution nmr: fast methods and heteronuclear direct detection. Chem. Phys. Chem., 2009, 10, 1356-1368.
64. Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering highaffinity ligands for proteins. Science, 1997, 278, 497, 499.
65. Sanchez, R.; Torres, D.; Prieto, J.; Blanco, F. J.; Campos-Olivas, R. Backbone assignment of human proliferating cell nuclear antigen. Biomol. NMR Assign, 2007, 1, 245-247.
66. Hajduk, P. J.; Gerfin, T.; Boehlen, J. M.; Haberli, M.; Marek, D.; Fesik, S. W. High-throughput nuclear magnetic resonance-based screening. J. Med. Chem., 1999, 42, 2315-2317.
67. Zartler, E. R.; Hanson, J.; Jones, B. E.; Kline, A. D.; Martin, G.; Mo, H.; Shapiro, M. J.; Wang, R.; Wu, H.; Yan, J. RAMPED-UP NMR: multiplexed NMR-based screening for drug discovery. J. Am. Chem. Soc., 2003, 125, 10941-10946.
68. Rothweiler, U.; Czarna, A.; Weber, L.; Popowicz, G. M.; Brongel, K.; Kowalska, K.; Orth, M.; Stemmann, O.; Holak, T. A. NMR screening for lead compounds using tryptophan-mutated proteins. J. Med. Chem., 2008, 51, 5035-5042.
69. Rothweiler, U.; Czarna, A.; Krajewski, M.; Ciombor, J.; Kalinski, C.; Khazak, V.; Ross, G.; Skobeleva, N.; Weber, L.; Holak, T. A. Isoquinolin-1-one inhibitors of the MDM2-p53 interaction. Chem. Med. Chem., 2008, 3, 1118-1128.
70. Rodriguez-Mias, R. A.; Pellecchia, M. Use of selective Trp side chain labeling to characterize protein-protein and protein-ligand interactions by NMR spectroscopy. J. Am. Chem. Soc., 2003, 125, 2892-2893.
71. D'Silva, L.; Ozdowy, P.; Krajewski, M.; Rothweiler, U.; Singh, M.; Holak, T. A. Monitoring the effects of antagonists on proteinprotein interactions with NMR spectroscopy. J. Am. Chem. Soc., 2005, 127, 13220-13226.
72. Krajewski, M.; Rothweiler, U.; D'Silva, L.; Majumdar, S.; Klein, C.; Holak, T. A. An NMR-based antagonist induced dissociation assay for targeting the ligand-protein and protein-protein interactions in competition binding experiments. J. Med. Chem., 2007, 50, 4382-4387.
73. Asensio, J. L.; Canada, F. J.; Jimenez-Barbero, J. Studies of the bound conformations of methyl alpha-lactoside and methyl betaallolactoside to ricin B chain using transferred NOE experiments in the laboratory and rotating frames, assisted by molecular mechanics and dynamics calculations. Eur. J. Biochem., 1995, 233, 618-630.
74. Stebbins, J. L.; Zhang, Z.; Chen, J.; Wu, B.; Emdadi, A.; Williams, M. E.; Cashman, J.; Pellecchia, M. Nuclear magnetic resonance fragment-based identification of novel FKBP12 inhibitors. J. Med. Chem., 2007, 50, 6607-6617.
75. Wei, J.; Kitada, S.; Rega, M. F.; Stebbins, J. L.; Zhai, D.; Cellitti, J.; Yuan, H.; Emdadi, A.; Dahl, R.; Zhang, Z.; Yang, L.; Reed, J. C.; Pellecchia, M. Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J. Med. Chem., 2009, 52, 4511-4523.
76. Chavez, M. I.; Andreu, C.; Vidal, P.; Aboitiz, N.; Freire, F.; Groves, P.; Asensio, J. L.; Asensio, G.; Muraki, M.; Canada, F. J.; Jimenez-Barbero, J. On the importance of carbohydrate-aromatic interactions for the molecular recognition of oligosaccharides by proteins: NMR studies of the structure and binding affinity of AcAMP2-like peptides with non-natural naphthyl and fluoroaromatic residues. Chemistry, 2005, 11, 7060-7074.
77. Hajduk, P. J.; Augeri, D. J.; Mack, J.; Mendoza, R.; Yang, J.; Betz, S. F.; Fesik, S. W. NMR-based screening of proteins containing 13C-labeled methyl groups. J. Am. Chem. Soc., 2000, 122, 7898-7904.
78. Tugarinov, V.; Hwang, P. M.; Kay, L. E. Nuclear magnetic resonance spectroscopy of high-molecular-weight proteins. Annu. Rev. Biochem., 2004, 73, 107-146.
79. Isaacson, R. L.; Simpson, P. J.; Liu, M.; Cota, E.; Zhang, X.; Freemont, P.; Matthews, S. A new labeling method for methyl transverse relaxation-optimized spectroscopy NMR spectra of alanine residues. J. Am. Chem. Soc., 2007, 129, 15428-15429.
80. Sattler, M.; Fesik, S. W. Use of deuterium labeling in NMR: overcoming a sizeable problem. Structure, 1996, 4, 1245-1249.
81. Pervushin, K.; Riek, R.; Wider, G.; Wuthrich, K. Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. Proc. Natl. Acad. Sci. USA, 1997, 94, 12366-12371.
82. Murray, C. W.; Verdonk, M. L. The consequences of translational and rotational entropy lost by small molecules on binding to proteins. J. Comput. Aided. Mol. Des., 2002, 16, 741-753.
83. Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. NMR-based screening in drug discovery. Q. Rev. Biophys., 1999, 32, 211-240.
84. McCoy, M. A.; Wyss, D. F. Alignment of weakly interacting molecules to protein surfaces using simulations of chemical shift perturbations. J. Biomol. NMR, 2000, 18, 189-198.
85. Lugovskoy, A. A.; Degterev, A. I.; Fahmy, A. F.; Zhou, P.; Gross, J. D.; Yuan, J.; Wagner, G. A novel approach for characterizing protein ligand complexes: molecular basis for specificity of smallmolecule Bcl-2 inhibitors. J. Am. Chem. Soc., 2002, 124, 1234-1240.
86. Cioffi, M.; Hunter, C. A.; Packer, M. J.; Spitaleri, A. Determination of protein-ligand binding modes using complexation-induced changes in 1H NMR chemical shift. J. Med. Chem., 2008, 51, 2512-2517.
87. McCoy, M. A.; Wyss, D. F. Spatial localization of ligand binding sites from electron current density surfaces calculated from NMR chemical shift perturbations. J. Am. Chem. Soc., 2002, 124, 11758-11763.
88. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol., 1997, 267, 727-748.
89. Hunter, C. A.; Packer, M. J. Complexation-Induced Changes in 1H NMR Chemical Shift for Supramolecular Structure Determination. Chem.- A Euro. J., 1999, 5, 1891-1897.
90. Stark, J.; Powers, R. Rapid protein-ligand costructures using chemical shift perturbations. J. Am. Chem. Soc., 2008, 130, 535-545.
91. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem., 2009, 9999, NA.
92. Linge, J. P.; O'Donoghue, S. I.; Nilges, M. Automated assignment of ambiguous nuclear overhauser effects with ARIA. Methods Enzymol., 2001, 339, 71-90.
93. Dominguez, C.; Boelens, R.; Bonvin, A. M. HADDOCK: a protein- protein docking approach based on biochemical or biophysical information. J. Am. Chem. Soc., 2003, 125, 1731-1737.
94. Schumann, F. H.; Riepl, H.; Maurer, T.; Gronwald, W.; Neidig, K. P.; Kalbitzer, H. R. Combined chemical shift changes and amino acid specific chemical shift mapping of protein-protein interactions. J. Biomol. NMR, 2007, 39, 275-289.
95. Takahashi, H.; Nakanishi, T.; Kami, K.; Arata, Y.; Shimada, I. A novel NMR method for determining the interfaces of large proteinprotein complexes. Nat. Struct. Biol., 2000, 7, 220-223.
96. Wells, J. A.; McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature, 2007, 450, 1001-1009.
97. Neuhaus, D.; P., W. M. The Nuclear Overhauser Effect in Structural and Conformational Analysis, 2nd ed.; Wiley-VCH, 2000.
98. Clore, G. M.; Gronenborn, A. M. Structures of larger proteins, protein-ligand and protein-DNA complexes by multi-dimensional heteronuclear NMR. Prog. Biophys. Mol. Biol., 1994, 62, 153-184.
99. Otting, G.; Wüthrich, K. Heteronuclear filters in two-dimensional 1H, 1H-NMR spectroscopy: combined use with isotope labelling for studies of macromolecular conformation and intermolecular interactions. Q. Rev. Biophys., 1990, 23, 39-96.
100. Breeze, A. L. Isotope-filtered NMR methods for the study of biomolecular structure and interactions. Prog. Nucl. Magn. Reson. Spectrosc., 2000, 36, 323-372.
101. Petros, A. M.; Kawai, M.; Luly, J. R.; Fesik, S. W. Conformation of two non-immunosuppressive FK506 analogs when bound to FKBP by isotope-filtered NMR. FEBS Lett., 1992, 308, 309-314.
102. McDonnell, P. A.; Constantine, K. L.; Goldfarb, V.; Johnson, S. R.; Sulsky, R.; Magnin, D. R.; Robl, J. A.; Caulfield, T. J.; Parker, R. A.; Taylor, D. S.; Adam, L. P.; Metzler, W. J.; Mueller, L.; Farmer, B. T., 2nd. NMR structure of a potent small molecule inhibitor bound to human keratinocyte fatty acid-binding protein. J. Med. Chem., 2006, 49, 5013-5017.
103. Tugarinov, V.; Choy, W. Y.; Orekhov, V. Y.; Kay, L. E. Solution NMR-derived global fold of a monomeric 82-kDa enzyme. Proc. Natl. Acad. Sci. USA, 2005, 102, 622-627.
104. Pellecchia, M.; Meininger, D.; Shen, A. L.; Jack, R.; Kasper, C. B.; Sem, D. S. SEA-TROSY (Solvent Exposed Amides with TROSY): A Method to Resolve the Problem of Spectral Overlap in Very Large Proteins. J. Am. Chem. Soc., 2001, 123, 4633-4634.
105. Lin, D.; Sze, K. H.; Cui, Y.; Zhu, G. Clean SEA-HSQC: a method to map solvent exposed amides in large non-deuterated proteins with gradient-enhanced HSQC. J. Biomol. NMR, 2002, 23, 317-322.
106. Gemmecker, G.; Jahnke, W.; Kessler, H. Measurement of fast proton exchange rates in isotopically labeled compounds. J. Am. Chem. Soc., 1993, 115, 11620-11621.
107. Pellecchia, M.; Meininger, D.; Dong, Q.; Chang, E.; Jack, R.; Sem, D. S. NMR-based structural characterization of large protein-ligand interactions. J. Biomol. NMR, 2002, 22, 165-173.
108. Medek, A.; Hajduk, P. J.; Mack, J.; Fesik, S. W. The use of differential chemical shifts for determining the binding site location and orientation of protein-bound ligands. J. Am. Chem. Soc., 2000, 122, 1241-1242.
109. Hajduk, P. J.; Mack, J. C.; Olejniczak, E. T.; Park, C.; Dandliker, P. J.; Beutel, B. A. SOS-NMR: a saturation transfer NMR-based method for determining the structures of protein-ligand complexes. J. Am. Chem. Soc., 2004, 126, 2390-2398.
110. Schieborr, U.; Vogtherr, M.; Elshorst, B.; Betz, M.; Grimme, S.; Pescatore, B.; Langer, T.; Saxena, K.; Schwalbe, H. How much NMR data is required to determine a protein-ligand complex structure? Chembiochem., 2005, 6, 1891-1898.
111. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta. Crystallogr. D. Biol. Crystallogr, 1998, 54, 905-921.
112. Kim, K. S.; Lu, S.; Cornelius, L. A.; Lombardo, L. J.; Borzilleri, R. M.; Schroeder, G. M.; Sheng, C.; Rovnyak, G.; Crews, D.; Schmidt, R. J.; Williams, D. K.; Bhide, R. S.; Traeger, S. C.; McDonnell, P. A.; Mueller, L.; Sheriff, S.; Newitt, J. A.; Pudzianowski, A. T.; Yang, Z.; Wild, R.; Lee, F. Y.; Batorsky, R.; Ryder, J. S.; Ortega-Nanos, M.; Shen, H.; Gottardis, M.; Roussell, D. L. Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 3937-3942.
113. McDonnell, P. A.; Yanchunas, J.; Newitt, J. A.; Tao, L.; Kiefer, S. E.; Ortega, M.; Kut, S.; Burford, N.; Goldfarb, V.; Duke, G. J.; Shen, H.; Metzler, W.; Doyle, M.; Chen, Z.; Tarby, C.; Borzilleri, R.; Vaccaro, W.; Gottardis, M.; Lu, S.; Crews, D.; Kim, K.; Lombardo, L.; Roussell, D. L. Assessing compound binding to the Eg5 motor domain using a thermal shift assay. Anal. Biochem., 2009, 392, 59-69.
114. Constantine, K. L.; Davis, M. E.; Metzler, W. J.; Mueller, L.; Claus, B. L. Protein-ligand NOE matching: a high-throughput method for binding pose evaluation that does not require protein NMR resonance assignments. J. Am. Chem. Soc., 2006, 128, 7252-7263.
115. Constantine, K. L.; Mueller, L.; Metzler, W. J.; McDonnell, P. A.; Todderud, G.; Goldfarb, V.; Fan, Y.; Newitt, J. A.; Kiefer, S. E.; Gao, M.; Tortolani, D.; Vaccaro, W.; Tokarski, J. Multiple and single binding modes of fragment-like kinase inhibitors revealed by molecular modeling, residue type-selective protonation, and nuclear overhauser effects. J. Med. Chem., 2008, 51, 6225-6229.
116. Wang, B.; Raha, K.; Merz, K. M., Jr. Pose scoring by NMR. J. Am. Chem. Soc., 2004, 126, 11430-11431.
117. Babaoglu, K.; Shoichet, B. K. Deconstructing fragment-based inhibitor discovery. Nat. Chem. Biol., 2006, 2, 720-723.
118. Brough, P. A.; Barril, X.; Borgognoni, J.; Chene, P.; Davies, N. G. M.; Davis, B.; Drysdale, M. J.; Dymock, B.; Eccles, S. A.; Garcia-Echeverria, C.; Fromont, C.; Hayes, A.; Hubbard, R. E.; Jordan, A. M.; Jensen, M. R.; Massey, A.; Merrett, A.; Padfield, A.; Parsons, R.; Radimerski, T.; Raynaud, F. I.; Robertson, A.; Roughley, S. D.; Schoepfer, J.; Simmonite, H.; Sharp, S. Y.; Surgenor, A.; Valenti, M.; Walls, S.; Webb, P.; Wood, M.; Workman, P.; Wright, L. Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to orally active 2-aminothieno2, 3-dpyrimidine inhibitors of the Hsp90 molecular chaperone. J. Med. Chem., 2009, 52, 4794-4809.
119. Koglin, A.; Klammt, C.; Trbovic, N.; Schwarz, D.; Schneider, B.; Schafer, B.; Lohr, F.; Bernhard, F.; Dotsch, V. Combination of cell-free expression and NMR spectroscopy as a new approach for structural investigation of membrane proteins. Magn. Reson. Chem., 2006, 44 Spec No, S17-23.
120. Ozawa, K.; Wu, P. S.; Dixon, N. E.; Otting, G. N-Labelled proteins by cell-free protein synthesis. Strategies for high-throughput NMR studies of proteins and protein-ligand complexes. FEBS J., 2006, 273, 4154-4159.
121. Staunton, D.; Schlinkert, R.; Zanetti, G.; Colebrook, S. A.; Campbell, I. D. Cell-free expression and selective isotope labelling in protein NMR. Magn. Reson. Chem., 2006, 44 Spec No, S2-9.
122. Dalvit, C.; Caronni, D.; Mongelli, N.; Veronesi, M.; Vulpetti, A. NMR-based quality control approach for the identification of false positives and false negatives in high throughput screening. Curr. Drug Discov. Technol., 2006, 3, 115-124.
123. Dalvit, C.; Fogliatto, G.; Stewart, A.; Veronesi, M.; Stockman, B. WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. J. Biomol. NMR, 2001, 21, 349-359.
124. Mayer, M.; Meyer, B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J. Am. Chem. Soc., 2001, 123, 6108-6117.
125. Shortridge, M. D.; Hage, D. S.; Harbison, G. S.; Powers, R. Estimating protein-ligand binding affinity using high-throughput screening by NMR. J. Comb. Chem., 2008, 10, 948-958.
126. Dalvit, C.; Fasolini, M.; Flocco, M.; Knapp, S.; Pevarello, P.; Veronesi, M. NMR-Based screening with competition water-ligand observed via gradient spectroscopy experiments: detection of highaffinity ligands. J. Med. Chem., 2002, 45, 2610-2614.
127. Wang, Y. S.; Liu, D.; Wyss, D. F. Competition STD NMR for the detection of high-affinity ligands and NMR-based screening. Magn. Reson. Chem., 2004, 42, 485-489.
128. Feher, K.; Groves, P.; Batta, G.; Jimenez-Barbero, J.; Muhle-Goll, C.; Kover, K. E. Competition saturation transfer difference experiments improved with isotope editing and filtering schemes in NMR-based screening. J. Am. Chem. Soc., 2008, 130, 17148-17153.
129. Dalvit, C.; Flocco, M.; Veronesi, M.; Stockman, B. J. Fluorine- NMR competition binding experiments for high-throughput screening of large compound mixtures. Comb. Chem. High Throughput Screen, 2002, 5, 605-611.
130. Zhang, X.; Sanger, A.; Hemmig, R.; Jahnke, W. Ranking of highaffinity ligands by NMR spectroscopy. Angew Chem. Int. Ed. Engl., 2009, 48, 6691-6694.
131. Hajduk, P. J.; Olejniczak, E. T.; Fesik, S. W. One-dimensional relaxation- and diffusion-edited NMR methods for screening compounds that bind to macromolecules. J. Am. Chem. Soc., 1997, 119, 12257-12261.
132. Lin, M.; Shapiro, M. J.; Wareing, J. R. Diffusion-Edited NMRAffinity NMR for Direct Observation of Molecular Interactions. J. Am. Chem. Soc., 1997, 119, 5249-5250.
133. Becker, B. A.; Morris, K. F.; Larive, C. K. An improved method for suppressing protein background in PFG NMR experiments to determine ligand diffusion coefficients in the presence of receptor. J. Magn Reson, 2006, 181, 327-330.
134. Lucas, L. H.; Larive, C. K. Measuring ligand-protein binding using NMR diffusion experiments. Concepts Magn. Reson., 2004, 20A, 24-41.
135. Vulpetti, A.; Hommel, U.; Landrum, G.; Lewis, R.; Dalvit, C. Design and NMR-based screening of LEF, a library of chemical fragments with different local environment of fluorine. J. Am. Chem. Soc., 2009, 131, 12949-12959.
136. Klein, J.; Meinecke, R.; Mayer, M.; Meyer, B. Detecting binding affinity to immobilized receptor proteins in compound libraries by HR-MAS STD NMR. J. Am. Chem. Soc., 1999, 121, 5336-5337.
137. Vanwetswinkel, S.; Heetebrij, R. J.; van Duynhoven, J.; Hollander, J. G.; Filippov, D. V.; Hajduk, P. J.; Siegal, G. TINS, target immobilized NMR screening: an efficient and sensitive method for ligand discovery. Chem. Biol., 2005, 12, 207-216.
138. Marquardsen, T.; Hofmann, M.; Hollander, J. G.; Loch, C. M.; Kiihne, S. R.; Engelke, F.; Siegal, G. Development of a dual cell, flow-injection sample holder, and NMR probe for comparative ligand-binding studies. J. Magn. Reson., 2006, 182, 55-65.
139. Jahnke, W. Spin labels as a tool to identify and characterize protein- ligand interactions by NMR spectroscopy. Chembiochem, 2002, 3, 167-173.
140. Jahnke, W.; Rudisser, S.; Zurini, M. Spin label enhanced NMR screening. J. Am. Chem. Soc., 2001, 123, 3149-3150.
141. Jahnke, W.; Perez, L. B.; Paris, C. G.; Strauss, A.; Fendrich, G.; Nalin, C. M. Second-site NMR screening with a spin-labeled first ligand. J. Am. Chem. Soc., 2000, 122, 7394-7395.
142. Jahnke, W.; Florsheimer, A.; Blommers, M. J.; Paris, C. G.; Heim, J.; Nalin, C. M.; Perez, L. B. Second-site NMR screening and linker design. Curr. Top. Med. Chem., 2003, 3, 69-80.
143. Vazquez, J.; Tautz, L.; Ryan, J. J.; Vuori, K.; Mustelin, T.; Pellecchia, M. Development of molecular probes for second-site screening and design of protein tyrosine phosphatase inhibitors. J. Med. Chem., 2007, 50, 2137-2143.
144. Jahnke, W.; Blommers, M. J.; Fernandez, C.; Zwingelstein, C.; Amstutz, R. Strategies for the NMR-based identification and optimization of allosteric protein kinase inhibitors. Chembiochem, 2005, 6, 1607-1610.
145. Vazquez, J.; De, S. K.; Chen, L. H.; Riel-Mehan, M.; Emdadi, A.; Cellitti, J.; Stebbins, J. L.; Rega, M. F.; Pellecchia, M. Development of paramagnetic probes for molecular recognition studies in protein kinases. J. Med. Chem., 2008, 51, 3460-3465.
146. Balogh, E.; Wu, D.; Zhou, G.; Gochin, M. NMR second site screening for structure determination of ligands bound in the hydrophobic pocket of HIV-1 gp41. J. Am. Chem. Soc., 2009, 131, 2821-2823.
147. Clore, G. M.; Tang, C.; Iwahara, J. Elucidating transient macromolecular interactions using paramagnetic relaxation enhancement. Curr. Opin. Struct. Biol., 2007, 17, 603-616.
148. Balaram, P.; Bothner-By, A. A.; Breslow, E. Nuclear magnetic resonance studies of the interaction of peptides and hormones with bovine neurophysin. Biochemistry, 1973, 12, 4695-4704.
149. Clore, G. M.; Gronenborn, A. M. Theory of the time dependent transferred nuclear overhauser effect: applications to structural analysis of ligand-protein complexes in solution. J. Magn. Reson., 1983, 53, 423-442.
150. Meyer, B.; Weimar, T.; Peters, T. Screening mixtures for biological activity by NMR. Eur. J. Biochem., 1997, 246, 705-709.
151. Politi, M.; Chávez, M. I.; Cañada, F. J.; Jiménez-Barbero, J. Screening by NMR: A new approach for the study of bioactive natural products? The example of Pleurotus ostreatus hot water extract. Eur. J. Org. Chem., 2005, 2005, 1392-1396.
152. Potenza, D.; Belvisi, L. Transferred-NOE NMR experiments on intact human platelets: receptor-bound conformation of RGDpeptide mimics. Org. Biomol. Chem., 2008, 6, 258-262.
153. Post, C. B. Exchange-transferred NOE spectroscopy and bound ligand structure determination. Curr. Opin. Struct. Biol., 2003, 13, 581-588.
154. Vincent, S. J.; Zwahlen, C.; Post, C. B.; Burgner, J. W.; Bodenhausen, G. The conformation of NAD+ bound to lactate dehydrogenase determined by nuclear magnetic resonance with suppression of spin diffusion. Proc. Natl. Acad. Sci. USA, 1997, 94, 4383-4388.
155. Jimenez-Barbero, J.; Asensio, J. L.; Canada, F. J.; Poveda, A. Free and protein-bound carbohydrate structures. Curr. Opin. Struct. Biol., 1999, 9, 549-555.
156. Kogelberg, H.; Solis, D.; Jimenez-Barbero, J. New structural insights into carbohydrate-protein interactions from NMR spectroscopy. Curr. Opin. Struct. Biol., 2003, 13, 646-653.
157. Jimenez-Barbero, J.; Canales, A.; Northcote, P. T.; Buey, R. M.; Andreu, J. M.; Diaz, J. F. NMR determination of the bioactive conformation of peloruside A bound to microtubules. J. Am. Chem. Soc., 2006, 128, 8757-8765.
158. Canales, A.; Matesanz, R.; Gardner, N. M.; Andreu, J. M.; Paterson, I.; Diaz, J. F.; Jimenez-Barbero, J. The bound conformation of microtubule-stabilizing agents: NMR insights into the bioactive 3D structure of discodermolide and dictyostatin. Chem.-A Euro. J., 2008, 14, 7557-7569.
159. Chen, A.; Shapiro, M. J. NOE Pumping. 2. A high-throughput method to determine compounds with binding affinity to macromolecules by NMR. J. Am. Chem. Soc., 2000, 122, 414-415.
160. Chen, A.; Shapiro, M. J. NOE Pumping: A novel NMR technique for identification of compounds with binding affinity to macromolecules. J. Am. Chem. Soc., 1998, 120, 10258-10259.
161. Li, D.; DeRose, E. F.; London, R. E. The inter-ligand Overhauser effect: a powerful new NMR approach for mapping structural relationships of macromolecular ligands. J. Biomol. NMR, 1999, 15, 71-76.
162. London, R.E. Theoretical analysis of the interligand overhauser effect: a new approach for happing structural relationships of macromolecular ligands. J. Magn. Reson., 1999, 141, 301-311.
163. Becattini, B.; Sareth, S.; Zhai, D.; Crowell, K. J.; Leone, M.; Reed, J. C.; Pellecchia, M. Targeting apoptosis via chemical design: inhibition of bid-induced cell death by small organic molecules. Chem. Biol., 2004, 11, 1107-1117.
164. Becattini, B.; Pellecchia, M. SAR by ILOEs: an NMR-based approach to reverse chemical genetics. Chemistry, 2006, 12, 2658-2662.
165. Becattini, B.; Culmsee, C.; Leone, M.; Zhai, D.; Zhang, X.; Crowell, K. J.; Rega, M. F.; Landshamer, S.; Reed, J. C.; Plesnila, N.; Pellecchia, M. Structure-activity relationships by interligand NOEbased design and synthesis of antiapoptotic compounds targeting Bid. Proc. Natl. Acad. Sci. USA, 2006, 103, 12602-12606.
166. Chen, J.; Zhang, Z.; Stebbins, J. L.; Zhang, X.; Hoffman, R.; Moore, A.; Pellecchia, M. A fragment-based approach for the discovery of isoform-specific p38alpha inhibitors. ACS Chem. Biol., 2007, 2, 329-336.
167. Sanchez-Pedregal, V. M.; Reese, M.; Meiler, J.; Blommers, M. J.; Griesinger, C.; Carlomagno, T. The INPHARMA method: proteinmediated interligand NOEs for pharmacophore mapping. Angew. Chem. Int. Ed. Engl., 2005, 44, 4172-4175.
168. Orts, J.; Griesinger, C.; Carlomagno, T. The INPHARMA technique for pharmacophore mapping: A theoretical guide to the method. J. Magn. Reson., 2009, 200(1), 64-73.
169. Bhat, R. K.; Berger, S. The 5S subunit of transcarboxylase interacts with free biotin as studied by transferred-NOESY and Saturation Transfer Difference NMR. Protein Pept. Lett., 2008, 15, 624-629.
170. Meyer, B.; Klein, J.; Mayer, M.; Meinecke, R.; Moller, H.; Neffe, A.; Schuster, O.; Wulfken, J.; Ding, Y.; Knaie, O.; Labbe, J.; Palcic, M. M.; Hindsgaul, O.; Wagner, B.; Ernst, B. Saturation transfer difference NMR spectroscopy for identifying ligand epitopes and binding specificities. Ernst Schering Res Found Workshop, 2004, 149-167.
171. Mayer, M.; Meyer, B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Ed., 1999, 38, 1784-1788.
172. Vogtherr, M.; Peters, T. Application of NMR Based Binding Assays to Identify Key Hydroxy Groups for Intermolecular Recognition. J. Am. Chem. Soc., 2000, 122, 6093-6099.
173. Kover, K. E.; Groves, P.; Jimenez-Barbero, J.; Batta, G. Molecular recognition and screening using a 15N group selective STD NMR method. J. Am. Chem. Soc., 2007, 129, 11579-11582.
174. Diercks, T.; Ribeiro, J. P.; Canada, F. J.; Andre, S.; Jimenez-Barbero, J.; Gabius, H. J. Fluorinated carbohydrates as lectin ligands: versatile sensors in f-19-detected saturation transfer difference NMR spectroscopy. Chem.-A Eur. J., 2009, 15, 5666-5668.
175. Rademacher, C.; Krishna, N. R.; Palcic, M.; Parra, F.; Peters, T. NMR experiments reveal the molecular basis of receptor recognition by a calicivirus. J. Am. Chem. Soc., 2008, 130, 3669-3675.
176. Benie, A. J.; Moser, R.; Bauml, E.; Blaas, D.; Peters, T. Virusligand interactions: Identification and characterization of ligand binding by NMR spectroscopy. J. Am. Chem. Soc., 2003, 125, 14-15.
177. Meinecke, R.; Meyer, B. Determination of the binding specificity of an integral membrane protein by saturation transfer difference NMR: RGD peptide ligands binding to integrin alphaIIbbeta3. J. Med. Chem., 2001, 44, 3059-3065.
178. Mari, S.; Serrano-Gómez, D.; Cañada, F. J.; Corbí, A. L.; Jiménez-Barbero, J. 1D Saturation Transfer Difference NMR Experiments on Living Cells: The DC-SIGN/Oligomannose Interaction. Angew. Chem. Int. Ed., 2005, 44, 296-298.
179. Claasen, B.; Axmann, M.; Meinecke, R.; Meyer, B. Direct observation of ligand binding to membrane proteins in living cells by a saturation transfer double difference (STDD) NMR spectroscopy method shows a significantly higher affinity of integrin alpha(IIb)beta3 in native platelets than in liposomes. J. Am. Chem. Soc., 2005, 127, 916-919.
180. Pereira, A.; Pfeifer, T. A.; Grigliatti, T. A.; Andersen, R. J. Functional cell-based screening and saturation transfer doubledifference nmr have identified haplosamate a as a cannabinoid receptor agonist. ACS Chem. Biol., 2009, 4, 139-144.
181. McCoy, M. A.; Senior, M. M.; Wyss, D. F. Screening of protein kinases by ATP-STD NMR spectroscopy. J. Am. Chem. Soc., 2005, 127, 7978-7979.
182. Langer, T.; Vogtherr, M.; Elshorst, B.; Betz, M.; Schieborr, U.; Saxena, K.; Schwalbe, H. NMR backbone assignment of a protein kinase catalytic domain by a combination of several approaches: application to the catalytic subunit of cAMP-dependent protein kinase. Chembiochem, 2004, 5, 1508-1516.
183. Rehders, D.; Claasen, B.; Redecke, L.; Buschke, A.; Reibe, C.; Jehmlich, N.; von Bergen, M.; Betzel, C.; Meyer, B. Peptide NMHRYPNQ of the cellular prion protein (PrP(C)) inhibits aggregation and is a potential key for understanding prion-prion interactions. J. Mol. Biol., 2009, 392, 198-207.
184. Krishna, N. R.; Jayalakshmi, V. Complete relaxation and conformational exchange matrix analysis of STD-NMR spectra of ligandreceptor complexes. Prog. Nucl. Magn. Reson. Spectrosc., 2006, 49, 1-25.
185. Dalvit, C.; Pevarello, P.; Tato, M.; Veronesi, M.; Vulpetti, A.; Sundstrom, M. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J. Biomol. NMR, 2000, 18, 65-68.
186. Bertini, I.; Dalvit, C.; Huber, J. G.; Luchinat, C.; Piccioli, M. ePHOGSY experiments on a paramagnetic protein: location of the catalytic water molecule in the heme crevice of the oxidized form of horse heart cytochrome c. FEBS Lett., 1997, 415, 45-48.
187. Ludwig, C.; Michiels, P. J.; Wu, X.; Kavanagh, K. L.; Pilka, E.; Jansson, A.; Oppermann, U.; Gunther, U. L. SALMON: solvent accessibility, ligand binding, and mapping of ligand orientation by NMR spectroscopy. J. Med. Chem., 2008, 51, 1-3.
188. Conner, M.; Hicks, M. R.; Dafforn, T.; Knowles, T. J.; Ludwig, C.; Staddon, S.; Overduin, M.; Gunther, U. L.; Thome, J.; Wheatley, M.; Poyner, D. R.; Conner, A. C. Functional and biophysical analysis of the C-terminus of the CGRP-receptor; a family B GPCR. Biochemistry, 2008, 47, 8434-8444.
189. Ludwig, C.; Michiels, P. J.; Lodi, A.; Ride, J.; Bunce, C.; Gunther, U. L. Evaluation of solvent accessibility epitopes for different dehydrogenase inhibitors. Chem. Med. Chem., 2008, 3, 1371-1376.
190. Michiels, P. J.; Ludwig, C.; Stephan, M.; Fischer, C.; Moller, G.; Adamski, J.; Messinger, J.; van Dongen, M.; Thole, H.; Gunther, U. L. Ligand-based NMR spectra demonstrate an additional phytoestrogen binding site for 17beta-hydroxysteroid dehydrogenase type 1. J. Steroid Biochem. Mol. Biol., 2009, 117(4-5), 93-98.
191. Gossert, A. D.; Henry, C.; Blommers, M. J.; Jahnke, W.; Fernandez, C. Time efficient detection of protein-ligand interactions with the polarization optimized PO-WaterLOGSY NMR experiment. J. Biomol. NMR, 2009, 43, 211-217.
192. Johnson, E. C.; Feher, V. A.; Peng, J. W.; Moore, J. M.; Williamson, J. R. Application of NMR SHAPES screening to an RNA target. J. Am. Chem. Soc., 2003, 125, 15724-15725.
193. Dalvit, C. Ligand- and substrate-based 19F NMR screening: Principles and applications to drug discovery. Prog. Nucl. Magn. Reson. Spectrosc., 2007, 51, 243-271.
194. Dalvit, C.; Ardini, E.; Flocco, M.; Fogliatto, G. P.; Mongelli, N.; Veronesi, M. A general NMR method for rapid, efficient, and reliable biochemical screening. J. Am. Chem. Soc., 2003, 125, 14620-14625.
195. Dalvit, C.; Ardini, E.; Fogliatto, G. P.; Mongelli, N.; Veronesi, M. Reliable high-throughput functional screening with 3-FABS. Drug Discov. Today, 2004, 9, 595-602.
196. Dalvit, C.; Papeo, G.; Mongelli, N.; Giordano, P.; Saccardo, B.; Costa, A.; Veronesi, M.; Ko, S. Y. Rapid NMR-based functional screening and IC50 measurements performed at unprecedentedly low enzyme concentration. Drug Dev. Res., 2005, 64, 105-113.
197. Papeo, G.; Giordano, P.; Brasca, M. G.; Buzzo, F.; Caronni, D.; Ciprandi, F.; Mongelli, N.; Veronesi, M.; Vulpetti, A.; Dalvit, C. Polyfluorinated amino acids for sensitive 19F NMR-based screening and kinetic measurements. J. Am. Chem. Soc., 2007, 129, 5665-5672.
198. Fattorusso, R.; Frutos, S.; Sun, X.; Sucher, N. J.; Pellecchia, M. Traditional Chinese medicines with caspase-inhibitory activity. Phytomedicine, 2006, 13, 16-22.
199. Tarrago, T.; Kichik, N.; Segui, J.; Giralt, E. The natural product berberine is a human prolyl oligopeptidase inhibitor. Chem. Med. Chem., 2007, 2, 354-359.
200. Frutos, S.; Tarrago, T.; Giralt, E. A fast and robust 19F NMRbased method for finding new HIV-1 protease inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 2677-2681.
201. Forino, M.; Johnson, S.; Wong, T. Y.; Rozanov, D. V.; Savinov, A. Y.; Li, W.; Fattorusso, R.; Becattini, B.; Orry, A. J.; Jung, D.; Abagyan, R. A.; Smith, J. W.; Alibek, K.; Liddington, R. C.; Strongin, A. Y.; Pellecchia, M. Efficient synthetic inhibitors of anthrax lethal factor. Proc. Natl. Acad. Sci. USA, 2005, 102, 9499-9504.
202. Stockman, B. J. 2-Fluoro-ATP as a versatile tool for 19F NMRbased activity screening. J. Am. Chem. Soc., 2008, 130, 5870-5871.
203. Lepre, C. A. Library design for NMR-based screening. Drug Discov. Today, 2001, 6, 133-140.
204. Jacoby, E.; Davies, J.; Blommers, M. J. Design of small molecule libraries for NMR screening and other applications in drug discovery. Curr. Top. Med. Chem., 2003, 3, 11-23.
205. Baurin, N.; Aboul-Ela, F.; Barril, X.; Davis, B.; Drysdale, M.; Dymock, B.; Finch, H.; Fromont, C.; Richardson, C.; Simmonite, H.; Hubbard, R. E. Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets. J. Chem. Inf. Comput. Sci., 2004, 44, 2157-2166.
206. Schuffenhauer, A.; Ruedisser, S.; Marzinzik, A. L.; Jahnke, W.; Blommers, M.; Selzer, P.; Jacoby, E. Library design for fragment based screening. Curr. Top. Med. Chem., 2005, 5, 751-762.
207. Siegal, G.; Ab, E.; Schultz, J. Integration of fragment screening and library design. Drug Discov. Today, 2007, 12, 1032-1039.
208. Blomberg, N.; Cosgrove, D. A.; Kenny, P. W.; Kolmodin, K. Design of compound libraries for fragment screening. J. Comput. Aided. Mol. Des. 2009.
209. Hubbard, R. E.; Chen, I.; Davis, B. Informatics and modeling challenges in fragment-based drug discovery. Curr. Opin. Drug Discov. Devel., 2007, 10, 289-297.
210. Hesterkamp, T.; Whittaker, M. Fragment-based activity space: smaller is better. Curr. Opin. Chem. Biol., 2008, 12, 260-268.
211. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 2005, 435, 677-681.
212. Hohwy, M.; Spadola, L.; Lundquist, B.; Hawtin, P.; Dahmen, J.; Groth-Clausen, I.; Nilsson, E.; Persdotter, S.; von Wachenfeldt, K.; Folmer, R. H.; Edman, K. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design. J. Med. Chem., 2008, 51, 2178-2186.
213. Edwards, P. D.; Albert, J. S.; Sylvester, M.; Aharony, D.; Andisik, D.; Callaghan, O.; Campbell, J. B.; Carr, R. A.; Chessari, G.; Congreve, M.; Frederickson, M.; Folmer, R. H.; Geschwindner, S.; Koether, G.; Kolmodin, K.; Krumrine, J.; Mauger, R. C.; Murray, C. W.; Olsson, L. L.; Patel, S.; Spear, N.; Tian, G. Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. J. Med. Chem., 2007, 50, 5912-5925.
214. Schade, M. NMR fragment screening: Advantages and applications. IDrugs, 2006, 9, 110-113.
215. Schade, M.; Oschkinat, H. NMR fragment screening: tackling protein-protein interaction targets. Curr. Opin. Drug Discov. Devel., 2005, 8, 365-373.
216. Fry, D. C.; Emerson, S. D.; Palme, S.; Vu, B. T.; Liu, C. M.; Podlaski, F. NMR structure of a complex between MDM2 and a small molecule inhibitor. J. Biomol. NMR, 2004, 30, 163-173.
217. Fry, D.; Sun, H. Utilizing peptide structures as keys for unlocking challenging targets. Mini Rev. Med. Chem., 2006, 6, 979-987.
218. Oblak, M.; Grdadolnik, S. G.; Kotnik, M.; Poterszman, A.; Atkinson, R. A.; Nierengarten, H.; Desplancq, D.; Moras, D.; Solmajer, T. Biophysical characterization of an indolinone inhibitor in the ATP-binding site of DNA gyrase. Biochem. Biophys. Res. Commun., 2006, 349, 1206-1213.
219. Fernández, C.; Jahnke, W. New approaches for NMR screening in drug discovery. Drug Discov. Today Technol., 2004, 1, 277-283.
220. Stockman, B. J.; Kothe, M.; Kohls, D.; Weibley, L.; Connolly, B. J.; Sheils, A. L.; Cao, Q.; Cheng, A. C.; Yang, L.; Kamath, A. V.; Ding, Y. H.; Charlton, M. E. Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H- 15N TROSY experiments. Chem. Biol. Drug Des., 2009, 73, 179-188.
221. Wyss, D. F.; Arasappan, A.; Senior, M. M.; Wang, Y. S.; Beyer, B. M.; Njoroge, F. G.; McCoy, M. A. Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening. J. Med. Chem., 2004, 47, 2486-2498.
222. Lepre, C. A.; Peng, J.; Fejzo, J.; Abdul-Manan, N.; Pocas, J.; Jacobs, M.; Xie, X.; Moore, J. M. Applications of SHAPES screening in drug discovery. Comb. Chem. High Throughput Screen, 2002, 5, 583-590.
223. Fejzo, J.; Lepre, C.; Xie, X. Application of NMR screening in drug discovery. Curr. Top. Med. Chem., 2003, 3, 81-97.
224. Tsao, D. H.; Sutherland, A. G.; Jennings, L. D.; Li, Y.; Rush, T. S., 3rd; Alvarez, J. C.; Ding, W.; Dushin, E. G.; Dushin, R. G.; Haney, S. A.; Kenny, C. H.; Malakian, A. K.; Nilakantan, R.; Mosyak, L. Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design. Bioorg. Med. Chem., 2006, 14, 7953-7961.
225. Ravi, M.; Zask, A.; Rush, T. S., 3rd. Structure-based identification of the binding site for the hemiasterlin analogue HTI-286 on tubulin. Biochemistry, 2005, 44, 15871-15879.
226. Rush, T. S., 3rd; Powers, R. The application of x-ray, NMR, and molecular modeling in the design of MMP inhibitors. Curr. Top. Med. Chem., 2004, 4, 1311-1327.
227. Bruncko, M.; Oost, T. K.; Belli, B. A.; Ding, H.; Joseph, M. K.; Kunzer, A.; Martineau, D.; McClellan, W. J.; Mitten, M.; Ng, S. C.; Nimmer, P. M.; Oltersdorf, T.; Park, C. M.; Petros, A. M.; Shoemaker, A. R.; Song, X.; Wang, X.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J. Med. Chem., 2007, 50, 641-662.
228. Irwin, J. J.; Shoichet, B. K. ZINC--a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model., 2005, 45, 177-182.
229. Fejzo, J.; Lepre, C. A.; Peng, J. W.; Bemis, G. W.; Ajay; Murcko, M. A.; Moore, J. M. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chem. Biol., 1999, 6, 755-769.
230. Pellecchia, M.; Becattini, B.; Crowell, K. J.; Fattorusso, R.; Forino, M.; Fragai, M.; Jung, D.; Mustelin, T.; Tautz, L. NMR-based techniques in the hit identification and optimisation processes. Exp. Opin. Ther. Targets, 2004, 8, 597-611.
231. Fattorusso, R.; Jung, D.; Crowell, K. J.; Forino, M.; Pellecchia, M. Discovery of a novel class of reversible non-peptide caspase inhibitors via a structure-based approach. J. Med. Chem., 2005, 48, 1649-1656.
232. Huang, J. W.; Zhang, Z.; Wu, B.; Cellitti, J. F.; Zhang, X.; Dahl, R.; Shiau, C. W.; Welsh, K.; Emdadi, A.; Stebbins, J. L.; Reed, J. C.; Pellecchia, M. Fragment-based design of small molecule Xlinked inhibitor of apoptosis protein inhibitors. J. Med. Chem., 2008, 51, 7111-7118.
233. Shahian, T.; Lee, G. M.; Lazic, A.; Arnold, L. A.; Velusamy, P.; Roels, C. M.; Guy, R. K.; Craik, C. S. Inhibition of a viral enzyme by a small-molecule dimer disruptor. Nat. Chem. Biol., 2009, 5, 640-646.
234. Huth, J. R.; Park, C.; Petros, A. M.; Kunzer, A. R.; Wendt, M. D.; Wang, X.; Lynch, C. L.; Mack, J. C.; Swift, K. M.; Judge, R. A.; Chen, J.; Richardson, P. L.; Jin, S.; Tahir, S. K.; Matayoshi, E. D.; Dorwin, S. A.; Ladror, U. S.; Severin, J. M.; Walter, K. A.; Bartley, D. M.; Fesik, S. W.; Elmore, S. W.; Hajduk, P. J. Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies. Chem. Biol. Drug Des., 2007, 70, 1-12.
235. Barker, J. J.; Barker, O.; Boggio, R.; Chauhan, V.; Cheng, R. K.; Corden, V.; Courtney, S. M.; Edwards, N.; Falque, V. M.; Fusar, F.; Gardiner, M.; Hamelin, E. M.; Hesterkamp, T.; Ichihara, O.; Jones, R. S.; Mather, O.; Mercurio, C.; Minucci, S.; Montalbetti, C. A.; Muller, A.; Patel, D.; Phillips, B. G.; Varasi, M.; Whittaker, M.; Winkler, D.; Yarnold, C. J. Fragment-based identification of Hsp90 inhibitors. Chem. Med. Chem., 2009, 4, 963-966.